YposKesi Welcomes Alain Lamproye, An Expert In Industrial Bioproduction, As Its Chief Executive Officer
Evry, France, February 28, 2017. YposKesi, the first French pharmaceutical company to develop and manufacture gene and cell therapy products for rare diseases, created by the nonprofit organization AFM-Téléthon and the SPI fund managed by Bpifrance, announced today the appointment of Alain Lamproye as its Chief Executive Officer. Alain Lamproye brings more than 25 years of experience in Europe and the United States in the field of industrial bioproduction. YposKesi will benefit from his unique expertise in bioproduction management and in the manufacturing of products generated from biotechnologies and gene therapy.
"Bioproduction is a key driver to help us make gene and cell therapies available to patients. At YposKesi, we enjoy an unparalleled synergy of skills to take up the challenge of industrialization of innovative treatment manufacturing for both rare and common diseases. We already produce drug candidate batches for academic, biotechnology and pharmaceutical organizations in Europe and the United States. Our ambitious strategy consists of expanding our production capacity, developing innovation and becoming a key player in the development of gene and cell therapy products," said Mr. Lamproye.
"We are delighted to welcome Alain Lamproye and his leadership to YposKesi," said Frédéric Revah, Chairman of YposKesi. "Supported by the exceptional resources invested in YposKesi by its founders, our ambition is to bring the potential of gene and cell therapies to patients".
Prior to joining YposKesi, Mr. Lamproye served as Chairman of the BioPharma Business Unit of Novasep since 2012, after having held the position of CEO of Novasep's subsidiary dedicated to Gene Therapy (Henogen, Belgium). He has worked for 9 years in pharmaceutical operations at Merck Serono, where he held various managerial positions, including Site Director at Billerica (USA). Prior to that experience, he worked as GMP Production Director at Eurogentec (Belgium) for 14 years. Alain holds a Master of Sciences from the University of Liège (Belgium).
About YposKesi
YposKesi (from the Greek Yposchesi, meaning 'promise') is the first French company to develop and produce gene and cell therapy products. Created in November 2016 by AFM-Téléthon and by the SPI fund managed by Bpifrance, this new company aims to make the first treatments available to patients and market them at a fair and controlled price, in accordance to the commitment made by its founders. Located in Evry (Essonne, France), this industrial platform is made up of more than 130 experts in bioproduction and has a first production building covering 5,000 m2 (formerly Généthon Bioprod). It is aiming at European leadership and, with this objective, by 2021 will bring together nearly 300 engineers, pharmacists, technicians and experts in three production buildings totaling 13,000 m2. It will thus meet the needs of AFM-Téléthon laboratories (Généthon and CECS/I-Stem), as well as those of academic and industrial biotechnology organizations, for clinical trials or post-MA (Marketing Authorization) distribution.
"Bioproduction is a key driver to help us make gene and cell therapies available to patients. At YposKesi, we enjoy an unparalleled synergy of skills to take up the challenge of industrialization of innovative treatment manufacturing for both rare and common diseases. We already produce drug candidate batches for academic, biotechnology and pharmaceutical organizations in Europe and the United States. Our ambitious strategy consists of expanding our production capacity, developing innovation and becoming a key player in the development of gene and cell therapy products," said Mr. Lamproye.
"We are delighted to welcome Alain Lamproye and his leadership to YposKesi," said Frédéric Revah, Chairman of YposKesi. "Supported by the exceptional resources invested in YposKesi by its founders, our ambition is to bring the potential of gene and cell therapies to patients".
Prior to joining YposKesi, Mr. Lamproye served as Chairman of the BioPharma Business Unit of Novasep since 2012, after having held the position of CEO of Novasep's subsidiary dedicated to Gene Therapy (Henogen, Belgium). He has worked for 9 years in pharmaceutical operations at Merck Serono, where he held various managerial positions, including Site Director at Billerica (USA). Prior to that experience, he worked as GMP Production Director at Eurogentec (Belgium) for 14 years. Alain holds a Master of Sciences from the University of Liège (Belgium).
About YposKesi
YposKesi (from the Greek Yposchesi, meaning 'promise') is the first French company to develop and produce gene and cell therapy products. Created in November 2016 by AFM-Téléthon and by the SPI fund managed by Bpifrance, this new company aims to make the first treatments available to patients and market them at a fair and controlled price, in accordance to the commitment made by its founders. Located in Evry (Essonne, France), this industrial platform is made up of more than 130 experts in bioproduction and has a first production building covering 5,000 m2 (formerly Généthon Bioprod). It is aiming at European leadership and, with this objective, by 2021 will bring together nearly 300 engineers, pharmacists, technicians and experts in three production buildings totaling 13,000 m2. It will thus meet the needs of AFM-Téléthon laboratories (Généthon and CECS/I-Stem), as well as those of academic and industrial biotechnology organizations, for clinical trials or post-MA (Marketing Authorization) distribution.